Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05902962 · ClinicalTrials.gov registry record · Phase 1
SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects
A Phase 1 study of Retinal Dystrophy and PRPF31 Mutationassociated Retinal Dystrophy, sponsored by PYC Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 6
- Study locations
NCT05902962: Active Phase 1 study of Retinal Dystrophy and PRPF31 Mutationassociated Retinal Dystrophy, sponsored by PYC Therapeutics.
NCT05902962 is a Phase 1 study of Retinal Dystrophy and PRPF31 Mutationassociated Retinal Dystrophy that is active but no longer recruiting, run by PYC Therapeutics. The registered enrollment target is 20 participants, below the 31-participant average among 3 other Retinal Dystrophy trials with a reported enrollment target (35% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05902962, a Phase 1 study of Retinal Dystrophy and PRPF31 Mutationassociated Retinal Dystrophy, is active but no longer recruiting, sponsored by PYC Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 6
- Study locations
Study Summary
A Phase 1 Open-Label, Single Arm Dose Escalation Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy
Conditions Studied
Interventions
- DRUG VP-001
Study Locations (6)
Florida
- University of Florida Health - Jacksonville
- Bascom Palmer Eye Institute University of Miami - Miami
Texas
- Retina Foundation of the Southwest - Dallas
- Baylor College of Medicine- Alkek Eye Center - Houston
Michigan
- University of Michigan Kellogg Eye Center - Ann Arbor
Oregon
- Oregon Health and Science University - Casey Eye Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-04-20 |
| Est. Completion | 2025-08-30 |
| Phase | Phase 1 |
What the registry record for NCT05902962 still lists
NCT05902962 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 31-participant average among 3 other Retinal Dystrophy trials with a reported enrollment target (35% lower).
The record links to 3 conditions, with Retinal Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which VP-001 is the first listed.
NCT05902962 lists 6 locations in 4 states (Florida, Texas, Michigan).
Frequently Asked Questions
What is clinical trial NCT05902962 about?
NCT05902962 is a clinical study titled "SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects". A Phase 1 Open-Label, Single Arm Dose Escalation Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy
What is the current status of trial NCT05902962?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2023-04-20. Estimated completion is 2025-08-30.
What conditions does trial NCT05902962 study?
This clinical trial studies the following conditions: Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy, RP11.
What interventions are being tested in trial NCT05902962?
The interventions under investigation include: VP-001 (DRUG).
Who is sponsoring clinical trial NCT05902962?
This trial is sponsored by PYC Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05902962 being conducted?
This trial has 6 study locations across Florida, Michigan, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinal Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oral Metformin for Treatment of ABCA4 Retinopathy
RECRUITING · Phase 1
-
Personalized Antisense Oligonucleotide Therapy for a Single Participant With PRPH2 Mutation Associated With Retinal Dystrophy
ACTIVE NOT RECRUITING · Phase 1
-
Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI